eli lilly retatrutide trial sign up Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Retatrutide, Eli Lilly's next obesity

10.1039/d1cs00468a 54 PengS.XiaoF.ChenM.GaoH

As a triple-agonist peptide that targets three key hormone pathways involved in appetite, metabolism, and energy regulation, it represents a significant leap forward from current medical weight loss programs

Most available evidence comes from in vitro and pre-clinical studies

Patients say they dont enjoy food as much. For patients unable to get hold of semaglutide, Leyla Hannbeck of the Association of Independent Multiple Pharmacists, suggests it may be possible to switch to another GLP-1 drug, saying: GPs can work out what the most appropriate replacement is. Novo Nordisk UK said it was trying to supply new stock of semaglutide as soon as possible